^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Signatera™

    Company:
    Natera
    Type:
    CE Marked
    Related tests:
    6d
    Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study) (clinicaltrials.gov)
    P=N/A, N=30, Suspended, Rutgers, The State University of New Jersey | Trial completion date: Nov 2024 --> Sep 2027 | Recruiting --> Suspended | Trial primary completion date: Nov 2024 --> Jun 2027
    Trial completion date • Trial suspension • Trial primary completion date • Circulating tumor DNA
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Signatera™
    7d
    SIGNAL GEC-101: Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer (clinicaltrials.gov)
    P=N/A, N=1000, Not yet recruiting, Natera, Inc.
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Signatera™
    |
    Imfinzi (durvalumab)
    7d
    The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC). (PubMed, Cancers (Basel))
    MRD was highly specific but less sensitive. Prospective studies are needed to define optimal testing intervals and validate MRD-guided strategies.
    Journal • Minimal residual disease
    |
    Signatera™ • GuardantREVEAL
    13d
    Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    Signatera™
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    19d
    ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab (clinicaltrials.gov)
    P4, N=90, Recruiting, NYU Langone Health | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene) • IFNA1 (Interferon Alpha 1)
    |
    Signatera™
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    25d
    Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment (clinicaltrials.gov)
    P2, N=15, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    Signatera™
    |
    AMB-05X
    27d
    Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR) (clinicaltrials.gov)
    P=N/A, N=50, Active, not recruiting, Nagoya City University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    Signatera™
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    27d
    Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas (clinicaltrials.gov)
    P1, N=22, Recruiting, University of California, Irvine | Trial completion date: Dec 2026 --> Jan 2028 | Trial primary completion date: Dec 2025 --> Jan 2027
    Trial completion date • Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    Signatera™
    |
    capecitabine • irinotecan • Lonsurf (trifluridine/tipiracil)
    1m
    Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience. (PubMed, JCO Precis Oncol)
    Personalized ctDNA testing demonstrated meaningful utility across HPB cancers, enabling early recurrence detection and guiding clinical decision making as a complementary tool in multidisciplinary care.
    Retrospective data • Journal • Real-world evidence • Circulating tumor DNA
    |
    AFP (Alpha-fetoprotein)
    |
    Signatera™
    1m
    SIGNAL-ER 101: Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer (clinicaltrials.gov)
    P=N/A, N=725, Recruiting, Natera, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Signatera™
    1m
    A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (clinicaltrials.gov)
    P2, N=20, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Apr 2026 --> Dec 2027
    Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    Signatera™
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
    1m
    Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment (clinicaltrials.gov)
    P2, N=15, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension • Circulating tumor DNA
    |
    Signatera™
    |
    AMB-05X